[go: up one dir, main page]

AR043143A1 - Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico - Google Patents

Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico

Info

Publication number
AR043143A1
AR043143A1 ARP040100410A ARP040100410A AR043143A1 AR 043143 A1 AR043143 A1 AR 043143A1 AR P040100410 A ARP040100410 A AR P040100410A AR P040100410 A ARP040100410 A AR P040100410A AR 043143 A1 AR043143 A1 AR 043143A1
Authority
AR
Argentina
Prior art keywords
hydraphy
therapeutic agent
sildenafil citrate
crystal variety
crystal
Prior art date
Application number
ARP040100410A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303097A external-priority patent/GB0303097D0/en
Priority claimed from GB0321309A external-priority patent/GB0321309D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR043143A1 publication Critical patent/AR043143A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una forma sólida de citrato de sildenafilo en la que la relación de sildenafilo: citrato es de 1:0,5. También se conoce como: 1-[[3-(6,7-dihidro-1-metil-7-oxo-3-propil-1H-pirazolo[4,3-d]pirimidir-5-il)-4-etoxifenil]sulfonil]-4-metilpiperazina.
ARP040100410A 2003-02-11 2004-02-10 Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico AR043143A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0303097A GB0303097D0 (en) 2003-02-11 2003-02-11 Crystalline therapeutic agent
GB0321309A GB0321309D0 (en) 2003-09-11 2003-09-11 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
AR043143A1 true AR043143A1 (es) 2005-07-20

Family

ID=32870944

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100410A AR043143A1 (es) 2003-02-11 2004-02-10 Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico

Country Status (3)

Country Link
AR (1) AR043143A1 (es)
TW (1) TW200500068A (es)
WO (1) WO2004072079A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1633364E (pt) * 2004-01-05 2008-05-29 Teva Pharma Métodos para a produção de sildenafil base e sal citrato de sildenafil
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
EA016037B1 (ru) 2005-04-19 2012-01-30 Никомед Гмбх Рофлумиласт для лечения лёгочной гипертензии
CN104940154A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种治疗泌尿外科疾病的药物枸橼酸西地那非组合物片剂
CN104940166A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种治疗男性阳痿的药物枸橼酸西地那非组合物胶囊
CN105147690A (zh) * 2015-09-28 2015-12-16 青岛华之草医药科技有限公司 一种治疗泌尿外科类疾病的药物枸橼酸西地那非组合物片剂
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
JP2024506942A (ja) 2021-02-18 2024-02-15 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
US6420557B1 (en) * 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
HUP0302982A3 (en) * 2000-07-28 2005-01-28 Pfizer Crystalline therapeutic agent

Also Published As

Publication number Publication date
TW200500068A (en) 2005-01-01
WO2004072079A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
DE60319406D1 (de) Meso-substituierte porphyrine
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
WO2004011611A3 (en) Taci antibodies and uses thereof
AR030245A1 (es) Composiciones de gel que contienen metronidazol
SG145701A1 (en) Piperazine derivatives and their use as therapeutic agents
SE0301653D0 (sv) Novel compounds
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
DE602005021501D1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
ATE412635T1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
AR043143A1 (es) Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico
BR0309053A (pt) Compostos
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
UY29952A1 (es) Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
ATE432710T1 (de) Pharmazeutische zusammensetzungen, die diaminooxidase enthalten
BR0210632A (pt) Tratamento de doença parasìtica
ATE399532T1 (de) Medizinische seife
CR8973A (es) Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua
CR8948A (es) Composicion farmaceutica
DE602004028408D1 (de) 4-ä(arylmethyl)aminomethylüpiperidinderivate, deren herstellung und deren anwendung in therapeutika
EA200801861A1 (ru) Активаторы плазминогена, имеющие сниженную способность связывать лизин
BRPI0412707A (pt) partìculas contendo um agente ativo na forma de um coprecipitado

Legal Events

Date Code Title Description
FB Suspension of granting procedure